Open Access

TBL1XR1 as a potential therapeutic target that promotes epithelial‑mesenchymal transition in lung squamous cell carcinoma

  • Authors:
    • Yuehua Zhao
    • Hao Lin
    • Jingwei Jiang
    • Mengxi Ge
    • Xiaohua Liang
  • View Affiliations

  • Published online on: November 12, 2018     https://doi.org/10.3892/etm.2018.6955
  • Pages: 91-98
  • Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Transducin (β)‑like 1 X‑linked receptor 1 (TBL1XR1) has been demonstrated to serve a vital role in tumor progression. However, the biological role and molecular mechanisms of TBL1XR1 in lung squamous cell carcinoma (SCC) remain largely unknown. The purpose of the present study was to investigate the biological role of TBL1XR1 and its mechanism in lung SCC. TBL1XR1 was expressed in a human bronchial epithelial cell line and in lung SCC cell lines. The present study analyzed TBL1XR1‑induced proliferation, invasion and migration abilities in vitro using the cell counting kit‑8 assay, cell invasion assay and wound healing assay, respectively. This study examined the effects of TBL1XR1 on epithelial‑mesenchymal transition (EMT) in lung SCC cells and activation of the transforming growth factor (TGF)‑β/mothers against decapentaplegic homolog (Smad) signaling pathway by western blotting. The results indicated that TBL1XR1 was upregulated in lung SCC cells. Overexpression of TBL1XR1 increased the rate of cell proliferation compared with the control group. In vitro, overexpression of TBL1XR1 promoted cell invasion and migration ability compared with the control group. In addition, overexpression of TBL1XR1 produced a mesenchymal phenotype, while cells with downregulated TBL1XR1 produced an epithelial phenotype. Overexpression of TBL1XR1 significantly increased E‑cadherin protein expression whilst snail family transcriptional repressor 1 (SNAI1), zinc finger E‑box binding homebox 1 (ZEB1), p‑Smad2/3, Smad2 and Smad3 protein expression was significantly reduced, compared with the control group. Downregulation of TBL1XR1 produced the opposite results. The present study indicated that TBL1XR1 contributed to lung SCC development and progression, and therefore TBL1XR1 may be a potential therapeutic target. TBL1XR1 may induce EMT of lung SCC cells through activation of the TGF‑β/Smad signaling pathway.
View Figures
View References

Related Articles

Journal Cover

January-2019
Volume 17 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhao Y, Lin H, Jiang J, Ge M and Liang X: TBL1XR1 as a potential therapeutic target that promotes epithelial‑mesenchymal transition in lung squamous cell carcinoma. Exp Ther Med 17: 91-98, 2019
APA
Zhao, Y., Lin, H., Jiang, J., Ge, M., & Liang, X. (2019). TBL1XR1 as a potential therapeutic target that promotes epithelial‑mesenchymal transition in lung squamous cell carcinoma. Experimental and Therapeutic Medicine, 17, 91-98. https://doi.org/10.3892/etm.2018.6955
MLA
Zhao, Y., Lin, H., Jiang, J., Ge, M., Liang, X."TBL1XR1 as a potential therapeutic target that promotes epithelial‑mesenchymal transition in lung squamous cell carcinoma". Experimental and Therapeutic Medicine 17.1 (2019): 91-98.
Chicago
Zhao, Y., Lin, H., Jiang, J., Ge, M., Liang, X."TBL1XR1 as a potential therapeutic target that promotes epithelial‑mesenchymal transition in lung squamous cell carcinoma". Experimental and Therapeutic Medicine 17, no. 1 (2019): 91-98. https://doi.org/10.3892/etm.2018.6955